177lu-dtpa-omburtamab - a radioimmunoconjugate consisting of omburtamab, a murine immunoglobulin g1 (igg1) antibody directed against the surface immunomodulatory glycoprotein human b7-homolog 3 (b7-h3, cd276), conjugated, via the chelating agent diethylenetriaminepentaacetic acid (dtpa), to the radioisotope lutetium lu 177, with potential antineoplastic activity. Upon intracerebroventricular administration of lutetium lu 177-dtpa-omburtamab, the omburtamab moiety binds to b7-h3 expressed on certain tumor cells. Upon binding, lutetium lu 177-dtpa-omburtamab delivers a cytotoxic dose of beta radiation to b7-h3-expressing cells. B7-h3, a type I transmembrane protein and a member of the b7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-h3 is a negative regulator of t-cell activation; its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and is correlated with poor prognosis.
Up to date info
Latest research - 177lu-dtpa-omburtamab
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 177lu-dtpa-omburtamab for any updates.